Skip to main content

Table 1 Intrathecal VZV-specific immune responses in patients with CIS/MS and VZV reactivation

From: The fraction of varicella zoster virus-specific antibodies among all intrathecally-produced antibodies discriminates between patients with varicella zoster virus reactivation and multiple sclerosis

 

IgGLoc(mean) (mg/l)

ABLoc(mean) (mg/l)

AB (serum) (mg/l)

AI

FSanti-VZV (%)**

CIS/MS (n = 20)

44.2 (5.6-103.1)

0.5 (0.1-4.5)

51 (7.6-353)

3.9 (1.6-14.8)

1.3 (0.3-5.3)

VZV (n = 7)*

20.7 (5.2-89.2)

8 (0.7-40.2)

244 (42.4-962)

6.9 (2.1-8.1)

45.1 (13.5-73)

  1. Median (range) of intrathecally-synthesized total IgG (IgGLoc (mean)), intrathecally-synthesized VZV-specific IgG (ABLoc (mean)), anti-VZV antibody concentration in serum (AB (serum)), antibody index (AI), and intrathecally-produced fraction of VZV-specific antibodies (FS) in patients with a clinically isolated syndrome or multiple sclerosis (CIS/MS) and VZV reactivation with central nervous system complications (VZV).
  2. *7 CSF/serum samples from 5 patients.
  3. **p = 0.0001 (CIS/MS vs. VZV).
Back to article page

Fluids and Barriers of the CNS

ISSN: 2045-8118